Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Supplementary Table 7 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
  1. Home
  2. Publications
  3. Supplementary Table 7 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner

Supplementary Table 7 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner

Authors:
  • LNLily L. Nguyen
    Lily L. Nguyen
  • ZWZachary L. Watson
    Zachary L. Watson
  • RORaquel Ortega
    Raquel Ortega
  • EWElizabeth R. Woodruff
    Elizabeth R. Woodruff
  • KJKimberly R. Jordan
    Kimberly R. Jordan
  • RIRitsuko Iwanaga
    Ritsuko Iwanaga
  • TYTomomi M. Yamamoto
    Tomomi M. Yamamoto
  • CBCourtney A. Bailey
    Courtney A. Bailey
  • FTFrancis To
    Francis To
  • SLShujian Lin
    Shujian Lin
  • FVFabian R. Villagomez
    Fabian R. Villagomez
  • AJAbigail D. Jeong
    Abigail D. Jeong

Open Access
Publisher website
Google Scholar
  • 17 June 2026
    • other
    • Published by American Association for Cancer Research (AACR)
    • DOI:10.1158/1541-7786.32714221
Abstract
Hallmark pathways enriched in ID8-R cells treated with combinatory UNC0642/Olaparib compared to UNC0642 alone.
Keywords
  • INHIBITION PROMOTES
  • DEPENDENT MANNER
  • SUPPLEMENTARY TABLE
  • PROMOTES REGRESSION
  • OVARIAN CANCER
  • CANCER TUMORS
  • MANNER HALLMARK
  • OLAPARIB COMPARED
  • THERAPY-RESISTANT OVARIAN
  • HALLMARK PATHWAYS
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.